Robust Bayesian hierarchical models for basket trials enabling joint evaluation of toxicity and efficacy
Zhi Cao, Pavel Mozgunov, Haiyan Zheng, [8pt] MRC Biostatistics Unit, University of Cambridge, U.K., [8pt] Email: [email protected] · 2025
Read Robust Bayesian hierarchical models for basket trials enabling joint evaluation of toxicity and efficacy by Zhi Cao, Pavel Mozgunov, Haiyan Zheng, [8pt] MRC Biostatistics Unit, University of Cambridge, U.K., [8pt] Email: [email protected] (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2505-10317.txt.
Introduction
Zhi Cao, Pavel Mozgunov, and Haiyan Zheng model basket trials in a 2025 statistics paper. Basket trials test one treatment across several patient subgroups at once, gaining speed. Most watch early benefit alone, yet safety needs joint watching. Their two Bayesian models read toxicity and efficacy together while letting subgroups differ.
One model treats each subgroup's paired effects as alike or distinct as a block. The other lets safety and benefit each choose their own sharing pattern. Robustness guards against one odd subgroup dragging the rest. Trial designers gain tools to borrow strength across baskets without blinding themselves to harm.
Catalog record
| CREATOR | Zhi Cao, Pavel Mozgunov, Haiyan Zheng, [8pt] MRC Biostatistics Unit, University of Cambridge, U.K., [8pt] Email: [email protected] |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2505-10317
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Robust Bayesian hierarchical models for basket trials enabling joint evaluation of toxicity and efficacy Zhi Cao, Pavel Mozgunov, Haiyan Zheng, [8pt] MRC Biostatistics Unit, University of Cambridge, U.K., [8pt] Email: [email protected] Abstract Basket trials have gained increasing attention for their efficiency, as multiple patient subgroups are evaluated simultaneously. Conducted basket trials focus primarily on establishing the early efficacy of a treatment, yet continued monitoring of toxicity is essential. In this paper, we propose two Bayesian hierarchical models that enable bivariate analyses of toxicity and efficacy, while accounting for heterogeneity present in the treatment effects across patient subgroups. Specifically, one assumes the subgroup-specific toxicity and efficacy treatment effects, as a parameter vector, can be exchangeable or non-exchangeable; the other allows either the toxicity or efficacy parameters specific to the subgroups, to be exchangeable or non-exchangeable. The bivariate exchangeability and non-exchangeability distributions introduce a correlation parameter between treatment effects, while we stipulate a zero correlation when only toxicity or efficacy parameters are exchangeable. Simulation results show that our models perform robustly under different scenarios compared to the standard Bayesian hierarchical model and the stand-alone analyses, especially in producing higher power when the subgroup-specific effects are exchangeable in toxicity or efficacy only. When considerable correlation between the toxicity and efficacy effects exists, our methodology gives small error rates and greater power than alternatives that analyse toxicity and efficacy by parts. Key words : Bivariate analysis; Borrowing strength; Exchangeability; Phase II; Robustness 1 Introduction Precision medicine has been recognised as a new frontier for healthcare due to the rapid development of genetics and biomedical techniques ( Hodson, 2016 ; Akhoon, 2021 ) . Patient heterogeneity is a key consideration for tailoring treatments based on the disease features. Consequently, the paradigm of drug development gradually moves away from one-size-fits-all approaches ( Cloitre, 2015 ) . In recent decades, innovative trial methodologies such as master protocols have emerged as feasible and efficient approaches to drug development in the era of precision medicine. Specifically, master protocols can streamline the design and analysis of clinical trials involving multiple patient strata to receive one or more treatments in a single overarching study ( Park et al., 2019 ) . Basket trials are one major type of master protocols in clinical trials: a new treatment can be evaluated simultaneously in several patient subgroups sharing a common disease feature which can, for example, be the same genetic aberration ( Hobbs et al., 2022 ) . For such commonality, borrowing of information across patient subgroups is a preferred approach to the analysis of basket trials. Thall et al., 2003 discussed a Bayesian hierarchical model to estimate the efficacy parameters specific to subgroups under the assumption of exchangeability. Explicitly, subgroup-specific treatment effects are assumed as random samples from the same underlying distribution and the joint distribution remains invariant irrespective to their permutations ( Bernardo, 2001 ) . Such hierarchical structure is commonly implemented for information borrowing. However, assuming the exchangeability of all treatment effects can be overly restrictive, which can lead to inaccurate estimates for subtrials with extreme observations. Here, subtrials are formed by the patient subgroups each within a basket trial. To relieve the concern, Neuenschwander et al., 2016 proposed a robust extension that accounts for possibility that each of the subtrial-specific parameter may be non-exchangeable with the others. Other innovative approaches for robust borrowing of information have been under development these years. For example, Hobbs and Landin, 2018 proposed exchangeability monitoring strategy using Bayesian monitoring rules for sharing information. Zheng and Wason, 2020 recommended information borrowing based on pair-wise discrepancies of treatment effects (monitoring the similarity of each pair of two subtrials to borrow information across those with high similarity). Besides, the adaptive clustering methods presuming more than one underlying distributions ( Chen and Lee, 2020 ) have been proposed to facilitate drug development. Basket trials are often conducted in phase II oncology settings to evaluate the efficacy of an anti-cancer therapy, which targets specific molecular alterations across different tumour types. Oncologic basket trials are predominantly non-randomized that all patients within a subtrial are treated with the single evaluated treatment (so-called single-arm design) for rapid assessment of efficacy. Notable examples include the BRAF-V600 cancer study utilizing vemurafenib, which demonstrated its applicability as a targetable oncogene across multiple malignancies ( Hyman et al., 2015 ) . The application of basket trials has extended beyond oncology to therapeutic areas such as neurodegenerative diseases. For instance, in neurodegenerative disorders research, basket trials have the potential to optimise resource use by testing various interventions within a unified framework ( Cummings et al., 2022 ) . Recent advancements have also introduced randomized basket trials and the use of continuous endpoints, such as the IMPACT II trial ( NCT02152254 ) which compares a targeted treatment against the standard therapy. An ongoing basket trial enrolls patients with Primary Biliary Cholangitis and participants with Parkinson’s disease, in which a continuous cognitive test score was measured to evaluate the efficacy ( ISRCTN15223158 ), thereby enhancing the rigour of therapeutic evaluations and biomarker development by incorporating randomisation procedure. ( Saad et al., 2017 ) In drug development, phase II clinical trials answer the question of whether the new treatment can be recommended to the confirmatory phase III trial. There is growing recognition that solely evaluating efficacy in phase II trials may neglect other crucial aspects, such as safety, tolerability, and broader pharmacodynamic responses. This can lead to misjudgments about a drug’s overall viability, especially when safety and other effects remain inadequately explored. Therefore, efficacy outcomes in Phase II trials may not always translate to Phase III success due to these overlooked factors. Besides, current statistical methodology to formally monitor toxicity data generally concentrates on single experimental treatment arm. Ivanova et al., 2005 proposed a method to continuously monitor toxicity in phase II trials as early-stopping rules. Ray and Rai, 2011 developed a mechanism combining toxicity monitoring with Simon’s two-stage design. More recently, a Bayesian multinomial model ( Sambucini, 2021 ) was established to jointly analyse discrete toxicity and efficacy. However, there is limited investigation concerning a formal appraisal of toxicity effects in phase II basket trials. In this article, we develop robust bivariate Bayesian analysis models for phase II basket trials to jointly evaluate toxicity and efficacy outcomes. The toxicity and efficacy effects will be formulated to allow a robust information borrowing across patient subgroups. Our proposed methods can be reviewed as the extensions of the exchangeable-nonexchangeable (EXNEX) model by Neuenschwander et al., 2016 : flexible prior mixture weights can be assigned to the exchangeability or non-exchangeability distributions of toxicity and efficacy parameters that imply different borrowing structures. Possible correlations between the toxicity and efficacy parameters are also taken into consideration in the bivariate analysis. The remainder of this article is structured as follows. In Section 2 , we describe how to model the basket trial data for a joint evaluation of toxicity and efficacy treatment effects. Two Bayesian models are proposed with consideration of robust information borrowing and inference. Section 3 presents a simulation study to assess the operating characteristics in comparisons with alternative methods. Finally, Section 4 will present a discussion on the proposed approaches. 2 Methods Consider a phase II randomised controlled basket trial with K subtrials, wherein